Skip to main content
. Author manuscript; available in PMC: 2016 May 27.
Published in final edited form as: Oncology (Williston Park). 2014 Nov;28(11):974–980.

Figure 2. Overall Survival as a Function of the Presence or Absence of Visceral Metastases in Men With mCRPC Treated With Abiraterone Acetate With or Without Prednisone.

Figure 2

Kaplan-Meier estimates of overall survival. The study was a post-hoc exploratory analysis of data from the COU-AA-301 trial.[12] Patients who had been treated with docetaxel were randomized to AA 1,000 mg (n = 797) or to placebo (n = 398), each with 5 mg prednisone twice a day. AA = abiraterone acetate; mCRPC = metastatic castration-resistant prostate cancer; OS = overall survival; P = prednisone; VD = visceral disease. Adapted from Goodman et al. Prostate Cancer Prostatic Dis. 2014.[12] Used with permission.